Literature DB >> 19680273

ARMS2/HTRA1 and CFH polymorphisms are not associated with choroidal neovascularization in highly myopic eyes of the elderly Japanese population.

H Nakanishi1, N Gotoh, R Yamada, K Yamashiro, A Otani, H Hayashi, A Tsujikawa, N Shimada, K Ohno-Matsui, M Mochizuki, M Saito, K Saito, T Iida, F Matsuda, N Yoshimura.   

Abstract

PURPOSE: The purpose of this study was to investigate whether the genetic risk factors of age-related macular degeneration (AMD) are associated with the development of choroidal neovascularization (CNV) in highly myopic eyes of elderly Japanese.
METHODS: Highly myopic elderly Japanese patients with and without CNV were genotyped for three AMD-associated single nucleotide polymorphisms (SNPs), namely rs10490924 (A69S) of ARMS2, rs11200638 of HTRA1, and rs1061170 (Y402H) of complement factor H (CFH), with the TaqMan SNP assay. One hundred and eighty-three unrelated highly myopic (axial lengths>26.00 mm or refractive errors>-6.0 diopters) Japanese patients with CNV who were >or=50 years of age (mean age+/-standard deviation of 62.7+/-6.3 years) and 170 highly myopic patients without CNV who were >or=50 years old (62.3+/-7.1 years) were studied. The differences in the genotypic distributions for the three SNPs between the two groups were tested with the Trend chi2 test, and logistic regression analyses were performed for age and gender adjustment.
RESULTS: No significant difference was detected in the distribution of the three SNPs, rs10490924 (P>0.1), rs11200638 (P>0.1), and rs1061170 (P>0.5), between the two groups even after adjustments for age and gender differences.
CONCLUSION: The genetic risk factors of AMD related to these SNPs do not contribute significantly to the development of CNV in a highly myopic elderly Japanese population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19680273     DOI: 10.1038/eye.2009.215

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  6 in total

1.  Genetic factors for choroidal neovascularization associated with high myopia.

Authors:  Nicolas Leveziel; Yi Yu; Robyn Reynolds; Albert Tai; Weihua Meng; Violaine Caillaux; Patrick Calvas; Bernard Rosner; François Malecaze; Eric H Souied; Johanna M Seddon
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-27       Impact factor: 4.799

2.  Therapeutic effect of oral bisphosphonates on choroidal neovascularization in the human eye.

Authors:  Shigeru Honda; Takayuki Nagai; Naoshi Kondo; Masahide Fukuda; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  J Ophthalmol       Date:  2010-07-25       Impact factor: 1.909

3.  Evaluation of 10 AMD Associated Polymorphisms as a Cause of Choroidal Neovascularization in Highly Myopic Eyes.

Authors:  Alvaro Velazquez-Villoria; Sergio Recalde; Jaouad Anter; Jaione Bezunartea; Maria Hernandez-Sanchez; Laura García-García; Elena Alonso; Jose María Ruiz-Moreno; Javier Araiz-Iribarren; Patricia Fernandez-Robredo; Alfredo García-Layana
Journal:  PLoS One       Date:  2016-09-19       Impact factor: 3.240

Review 4.  Characteristics of Pachychoroid Diseases and Age-Related Macular Degeneration: Multimodal Imaging and Genetic Backgrounds.

Authors:  Kenji Yamashiro; Yoshikatsu Hosoda; Masahiro Miyake; Sotaro Ooto; Akitaka Tsujikawa
Journal:  J Clin Med       Date:  2020-06-29       Impact factor: 4.241

5.  Association of paired box 6 with high myopia in Japanese.

Authors:  Masahiro Miyake; Kenji Yamashiro; Hideo Nakanishi; Isao Nakata; Yumiko Akagi-Kurashige; Akitaka Tsujikawa; Muka Moriyama; Kyoko Ohno-Matsui; Manabu Mochizuki; Ryo Yamada; Fumihiko Matsuda; Nagahisa Yoshimura
Journal:  Mol Vis       Date:  2012-11-17       Impact factor: 2.367

6.  Myopia in Chinese families shows linkage to 10q26.13.

Authors:  Anthony M Musolf; Claire L Simpson; Kyle A Long; Bilal A Moiz; Deyana D Lewis; Candace D Middlebrooks; Laura Portas; Federico Murgia; Elise B Ciner; Joan E Bailey-Wilson; Dwight Stambolian
Journal:  Mol Vis       Date:  2018-01-14       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.